Lessons From the Real World: Treating High Risk HR+/HER2- Breast Cancer According to the Latest Evidence

Risk vs Biology: Which carries more weight in the decision to escalate therapy?

Credit available for this activity expires: 04/21/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/lessons-real-world-treating-high-risk-hr-her2-breast-cancer-2026a1000bhd?ecd=bdc_podcast_libsyn_mscpedu